GlobeNewswire by notified

CoinShares XBT Provider AB (Publ) - 2023 Audited Financial Statements for the Year Ended 31 December 2023

Share

30 April 2024

CoinShares XBT Provider AB (Publ)

LEI: 549300HGWKR2Q5T8GK64

CoinShares XBT Provider AB (Publ) - 2023 Audited Financial Statements for the Year Ended 31 December 2023

Stockholm, 30 April 2024 -- CoinShares XBT Provider AB (Publ) (the "Company") announces that the Annual Report and Audited Accounts for the year ended 31 December 2023 were published and posted on 30 April 2024 on the Company website.

The audited accounts for the Guarantor, CoinShares Capital Markets (Jersey) Limited, for the year ended 31 December 2023 are also available on the website.

Interested persons may access electronic copies of these documents at https://etp.coinshares.com/documents

About CoinShares XBT Provider

CoinShares XBT Provider AB (Publ) (“CoinShares XBT Provider”), a CoinShares company, is the Swedish-domiciled issuer of the Bitcoin Tracker One (SE0007126024), Bitcoin Tracker Euro (SE0007525332), Ether Tracker One (SE0010296574), Ether Tracker Euro (SE0010296582), series of certificates (collectively, the “Certificates”) which are designed to synthetically track the performance of the price of the relevant underlying crypto-asset, bitcoin or ether, (in Swedish Krona or Euro, respectively), less a fee component.

In 2015, Bitcoin Tracker One became the first bitcoin-referenced security available on a regulated exchange when it listed on Nasdaq Stockholm. In 2017, Ether Tracker One became the first ether-referenced security available on a regulated exchange when it listed on Nasdaq Stockholm. The Certificates are available and traded in the same manner as any other share or instrument listed on their respective exchanges.

CoinShares XBT Provider’s Prospectus is approved by the Swedish Financial Supervisory Authority (Sw. Finansinspektionen) and the Certificates are governed by Swedish law. CoinShares XBT Provider is not a licensed financial advisor. The views presented in this release are the opinions of the Board of CoinShares XBT Provider and no other party. Bitcoin and ether, are volatile assets and their prices (and the price of securities that are referenced to them) can move quickly, positively or negatively. Prospective investors in the Certificates should carefully consider the suitability of such an investment and whether they have sufficient financial resources in order to be able to bear the risks associated therewith and, in connection with such a determination, should carefully read CoinShares XBT Provider’s latest Prospectus (including, in particular, the risk warnings set out therein). The Certificates do not confer on the holders thereof any claim to or against the relevant underlying crypto-asset to which they are referenced. The value and any payment due under the Certificates will be affected by the exchange rate between the US Dollar and the Euro or, as the case may be, between the US Dollar and the Swedish Kronor. Any returns upon the Certificates will not be the same as the returns which a direct investment of an equivalent sum in the relevant underlying crypto-asset could produce. The Certificates are non-equity linked, non-principal protected, unsecured and unsubordinated and do not bear interest.

Certificates are non-equity linked, non-principal protected, unsecured and unsubordinated and do not bear interest.

For further information, please contact:

CoinShares XBT Provider AB (Publ)
Artillerigatan 6,
114 51 Stockholm
Sweden
ir@xbtprovider.com

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

Alvotech and Dr. Reddy’s enter into collaboration for commercialization of AVT03 (denosumab), a biosimilar candidate to Prolia® & Xgeva® in the U.S., Europe and UK21.5.2024 14:01:00 CEST | Press release

Dr. Reddy’s gets exclusive commercialization rights in the United States (U.S.) as well as semi-exclusive rights in Europe and United Kingdom (UK)Alvotech will be responsible for development and manufacture of the product HYDERABAD, INDIA & REYKJAVIK, ICELAND — Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide (“Alvotech”), and Dr. Reddy’s Laboratories SA, wholly-owned subsidiary of Dr. Reddy’s Laboratories Ltd., (BSE: 500124 | NSE: DRREDDY | NYSE: RDY | NSEIFSC: DRREDDY, along with its subsidiaries hereafter referred to as “Dr. Reddy’s”), today announced that the companies have entered into a license and supply agreement for the commercialization of AVT03, Alvotech’s biosimilar candidate to Prolia® and Xgeva® (denosumab). The collaboration combines Dr. Reddy’s global commercial presence with Alvotech’s proven capabilities in developing biosimilars for markets worldwide. Prolia® and Xgeva® ar

FDH Aero Appoints John Cuomo to its Board of Directors21.5.2024 14:00:00 CEST | Press release

COMMERCE, Calif., May 21, 2024 (GLOBE NEWSWIRE) -- FDH Aero (“FDH”), a global provider of supply chain solutions for the aerospace and defense industry, today announced the appointment of John Cuomo to the FDH Aero board. John is a seasoned aviation industry executive and experienced board member who brings more than 25 years of aerospace, defense, distribution and supply chain experience to FDH. “We are delighted to welcome John to our board, where his extensive expertise will undoubtedly have an immediate influence on our business and further enhance our ability to drive continued growth and deliver exceptional value to our clients,” said Scott Tucker, FDH CEO. “John has driven significant value creation both during his time at KLX and currently at VSE and has experience working with, and scaling, businesses of all sizes and at all stages of development. John’s depth of experience will be invaluable as FDH continues to scale organically and through acquisitions.” "I am honored to joi

Scandinavian Tobacco Group A/S: Transactions in connection with share buy-back programme21.5.2024 14:00:00 CEST | Press release

Company Announcement No.28/2024 Copenhagen, 21 May 2024 Transactions in connection with share buy-back programme On 10 November 2023, Scandinavian Tobacco Group A/S announced that a share buy-back programme of an aggregated value of up to DKK 850 million was launched with the purpose to adjust the Company’s capital structure and meet obligations relating to the Group’s share-based incentive programme. Part of the programme will be conducted in accordance with Regulation No. 596/2014 of the European Parliament and Council of 16 April 2014 (the “Market Abuse Regulation”) and Commission Delegated Regulation (EU) 2016/1052, also referred to as the Safe Harbour rules. Another part of the share buy-back programme is conducted as a directed buy-back from Chr. Augustinus Fabrikker Aktieselskab and C.W. Obel A/S as further described in company announcement no. 30/2023. The share buy-back programme will end no later than 28 February 2025. The following transactions have been executed from 13 May

EVP and Chief Medical Officer Laurence de Moerlooze Will Be Leaving Bavarian Nordic21.5.2024 14:00:00 CEST | Press release

COPENHAGEN, Denmark, May 21, 2024 – Bavarian Nordic A/S (OMX: BAVA) today announced that Laurence de Moerlooze will leave her position as Executive Vice President and Chief Medical Officer in the Company to pursue new opportunities. She will continue to support Bavarian Nordic until the end of May 2024. The Company will initiate a search process to identify the next Chief Medical Officer. Paul Chaplin, President & CEO of Bavarian Nordic, said: “On behalf of everyone at Bavarian Nordic, I want to express my gratitude to Laurence for her significant contributions to the company during our commercial transformation over the past years. Laurence joined in 2020, tasked with building a development function to support our growing commercial footprint. Through the establishment of global medical, pharmacovigilance and regulatory teams as well as a clinical organization purposed to drive continued product lifecycle management and pipeline development, these objectives have now been achieved, an

Laurence de Moerlooze fratræder som EVP og Chief Medical Officer i Bavarian Nordic21.5.2024 14:00:00 CEST | pressemeddelelse

KØBENHAVN, Danmark, 21. maj 2024 – Bavarian Nordic A/S (OMX: BAVA) meddelte i dag, at Laurence de Moerlooze har valgt at fratræde sin stilling som Executive Vice President og Chief Medical Officer i selskabet for at søge nye udfordringer. Hun fortsætter sit virke i Bavarian Nordic indtil udgangen af maj 2024. Selskabet vil iværksætte en søgning med henblik på ansættelse af en ny Chief Medical Officer. Paul Chaplin, administrerende direktør i Bavarian Nordic, udtaler: “På vegne af alle i Bavarian Nordic vil jeg gerne takke Laurence for hendes væsentlige bidrag til selskabet gennem vores kommercielle transformation over de seneste år. Laurence tiltrådte i 2020 for at opbygge en udviklingsafdeling, der kunne understøtte vores voksende kommercielle forretning. Med etableringen af globale medicinske og regulatoriske teams samt en klinisk organisation, der er tilpasset til den fortsatte lifecycle management af produktporteføljen og udvikling af pipelinen, er disse mål nu opfyldt. Laurence ha

HiddenA line styled icon from Orion Icon Library.Eye